Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Russia’s Roszdravnadzor raises concerns about phantom drug wholesale companies

This article was originally published in RAJ Devices

Executive Summary

During a country-wide inspection carried out in July and August 2008, the Russian Service for the Surveillance of Healthcare and Social Development (Roszdravnadzor) has discovered over 60 drug wholesale companies that do not provide their services in places stipulated in their licences. This, the authority believes, could mean that these firms are involved in criminal activities having the potential to put patients’ health at risk. In light of an ongoing discussion in Russia about cutting licensing requirements to eliminate bureaucratic barriers, Roszdravnadzor suggests that the drug distribution market is not ready for control over the sector to be relaxed in order to ease entry to the market.

You may also be interested in...



MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins

In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.

EMA Acts To Freeze GVK Drugs, Guard Against Shortages

The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.

EMA Acts To Freeze Drugs Linked to GVK Bio, Guards Against Shortages

EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.

UsernamePublicRestriction

Register

SC143384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel